|
| Press Releases |
|
 |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
BDO公布「2024年第六届BDO 环境、社会及管治大奖」得奖名单
Dec 11, 2024 22:20 HKT/SGT
|
|
|
物流行业乘政策东风 顺丰控股价值股属性凸显
Dec 11, 2024 22:11 HKT/SGT
|
|
|
BDO公佈「2024年第六屆BDO 環境、社會及管治大獎」得獎名單
Dec 11, 2024 22:10 HKT/SGT
|
|
|
物流行業乘政策東風 順豐控股價值股屬性凸顯
Dec 11, 2024 22:05 HKT/SGT
|
|
|
BDO announces winners of the 6th BDO ESG Awards 2024
Dec 11, 2024 22:00 HKT/SGT
|
|
|
GMG's THERMAL-XR(R) Demonstrates Potential for Electronics Heat Sink Miniaturization and Efficiency
Dec 11, 2024 21:29 HKT/SGT
|
|
|
Volatus Aerospace Welcomes UK-Based Air Data Systems to its Ecosystem, Expanding Global Capabilities
Dec 11, 2024 20:45 HKT/SGT
|
|
|
Intelligent Joy Limited Signs MOU for Strategic Cooperation with First U.S. Capital Group (Revised)
Dec 11, 2024 18:30 HKT/SGT
|
|
|
富士通コミュニケーションサービス株式会社の株式譲渡契約の締結について
Dec 11, 2024 16:15: JST
|
|
|
Brawijaya University develops data system for climate change monitoring
Dec 11, 2024 15:40 HKT/SGT
|
|
|
Fujitsu concludes share transfer agreement concerning Fujitsu Communication Services Limited
Dec 11, 2024 16:36 JST
|
|
|
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 11, 2024 14:45 JST
|
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT/SGT
|
|
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位
Dec 11, 2024 11:02 HKT/SGT
|
|
|
富士通、東洋大学、ココロバランス研究所、適切な対応の習得を支援するカスタマーハラスメント体験AIツールを活用した教育プログラムの実証実験を開始
Dec 11, 2024 11:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
